| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
169,410,000 |
| Market
Cap: |
97.83(M) |
| Last
Volume: |
3,856,623 |
Avg
Vol: |
3,846,008 |
| 52
Week Range: |
$0.35 - $0.885 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies, all of which utilize the two components of Co.'s integrated platform, SynCon® and CELLECTRA®. Co. is evaluating the feasibility of, conducting or planning clinical studies of its DNA medicines.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
5,700 |
37,076 |
| Total Sell Value |
$0 |
$0 |
$3,192 |
$60,923 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
1 |
5 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Miller Ann Calby |
Director |
– • – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
7,710 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2024-05-15 |
4 |
D |
$13.07 |
$100,874 |
D/D |
(7,718) |
33,647 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,745 |
41,365 |
|
- |
|
| Sumner Michael John |
Chief Medical Officer |
• – – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,386 |
5,302 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
82,509 |
|
- |
|
| Yarno Wendy L |
Director |
– • – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
8,345 |
|
- |
|
| Benito Simon X |
Director |
– • – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
10,024 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2024-05-15 |
4 |
D |
$13.07 |
$33,485 |
D/D |
(2,562) |
24,367 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,771 |
26,929 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2024-05-15 |
4 |
D |
$13.07 |
$22,258 |
D/D |
(1,703) |
24,337 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,771 |
26,040 |
|
- |
|
| Shepard Jay |
Director |
– • – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
7,042 |
|
- |
|
| Zoth Lota S |
Director |
– • – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
6,559 |
|
- |
|
| Dansey Roger D |
Director |
– • – |
2024-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
6,749 |
|
- |
|
| Dansey Roger D |
Director |
– • – |
2024-05-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,000 |
4,583 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2024-05-10 |
4 |
D |
$10.65 |
$25,475 |
D/D |
(2,392) |
23,620 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2024-05-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,500 |
26,012 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,916 |
80,343 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2024-02-26 |
4 |
D |
$8.16 |
$28,283 |
D/D |
(3,466) |
22,158 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,875 |
24,516 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2024-02-26 |
4 |
D |
$8.16 |
$19,184 |
D/D |
(2,351) |
21,269 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,734 |
22,850 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2024-02-26 |
4 |
D |
$8.16 |
$30,420 |
D/D |
(3,728) |
20,512 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,731 |
23,368 |
|
- |
|
| Sumner Michael John |
Chief Medical Officer |
• – – |
2023-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
|
- |
|
505 Records found
|
|
Page 1 of 21 |
|
|
